Compare Amgen, Inc. (AMGN) vs United States Copper Index Fund (CPER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs United States Copper Index Fund — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while United States Copper Index Fund trades at $37.8. The key difference: Amgen, Inc. pays a 2.77% dividend while United States Copper Index Fund pays none. Which is the better fit depends on your goals.
| AMGN | CPER | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $388.16 | $40.60 |
52-Week Low | $271.18 | $27.21 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CPER (United States Copper Index Fund) trades at $37.99, up 0.64% with a bullish technical signal from moving averages. The ETF provides exposure to copper futures, benefiting from industrial demand driven by electrification and AI infrastructure. Recent news highlights copper's outperformance versus gold and silver in 2026, with supply constraints and strong demand supporting prices.
The outlook remains positive given structural demand trends, though risks include global manufacturing weakness and commodity price volatility. Analyst sentiment favors copper's role in the energy transition, but investors should monitor economic indicators that could impact industrial metal demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →
